Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 09/18 03:59:58 pm
126.6 EUR   +2.06%
08:48aMERCK : Agenda
PU
05:43aMERCK KGAA : Buy rating from Independant Research
MD
03:10aMERCK : BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/14/2020 09/15/2020 09/16/2020 09/17/2020 09/18/2020 Date
123.15(c) 122.6(c) 124.3(c) 124.05(c) 126.75 Last
310 745 466 755 415 347 276 406 783 630 Volume
+0.94% -0.45% +1.39% -0.20% +2.18% Change
More quotes
Financials
Sales 2020 17 299 M 20 480 M 20 480 M
Net income 2020 1 688 M 1 998 M 1 998 M
Net Debt 2020 10 712 M 12 681 M 12 681 M
P/E ratio 2020 31,3x
Yield 2020 1,07%
Sales 2021 18 153 M 21 491 M 21 491 M
Net income 2021 2 108 M 2 495 M 2 495 M
Net Debt 2021 8 815 M 10 436 M 10 436 M
P/E ratio 2021 24,9x
Yield 2021 1,14%
Capitalization 53 934 M 63 767 M 63 852 M
EV / Sales 2020 3,74x
EV / Sales 2021 3,46x
Nbr of Employees 57 523
Free-Float 29,7%
More Financials
Company
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - pharmaceutical products (41.6%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - solutions and products for scientific and biotechnological research... 
Sector
Pharmaceuticals
Calendar
09/23Presentation
More about the company
Notations Surperformance© of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
All news about MERCK KGAA
08:48aMERCK : Agenda
PU
05:43aMERCK KGAA : Buy rating from Independant Research
MD
03:10aMERCK : BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The ..
PU
09/17MERCK KGAA : JP Morgan gives a Neutral rating
MD
09/17MERCK KGAA : Credit Suisse gives a Buy rating
MD
09/16MERCK KGAA : Bernstein remains Neutral
MD
09/16MERCK : says it has overcome production shortages in vaccine materials
RE
09/16MERCK KGAA : JP Morgan sticks Neutral
MD
09/16MERCK KGAA : Goldman Sachs reiterates its Sell rating
MD
09/16MERCK : Confirms 2020 Outlook; Prioritizes Lower Debt
DJ
09/16MERCK : Germany's Merck says it will focus on smaller takeovers
RE
09/15MERCK KGAA : JP Morgan remains Neutral
MD
09/14MERCK KGAA : Darmstadt, Germany Announces Positive Phase II Results for Investig..
AQ
09/14MERCK KGAA : Morgan Stanley remains Neutral
MD
09/13MERCK : Darmstadt, Germany, Advances Oncology Portfolio and Pipeline with New an..
PU
More news
News in other languages on MERCK KGAA
05:43aMERCK KGAA : Independant Research optimiste sur le dossier
05:43aIndependent hebt Ziel für Merck KGaA auf 138 Euro - 'Kaufen'
09/17MERCK KGAA : JP Morgan maintient son opinion neutre
09/17JPMorgan belässt Merck KGaA auf 'Neutral' - Ziel 130 Euro
09/17MERCK KGAA : Credit Suisse favorable sur le dossier
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 120,57 €
Last Close Price 124,05 €
Spread / Highest target 20,9%
Spread / Average Target -2,81%
Spread / Lowest Target -25,8%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA17.75%63 767
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD122.99%21 854
KYOWA KIRIN CO., LTD.12.40%14 826
BETTA PHARMACEUTICALS CO., LTD.70.93%6 687
YUHAN CORPORATION40.38%3 549
RECIPHARM AB (PUBL)19.30%1 793